较低睾酮水平与非转移性去势抵抗性前列腺癌患者接受新型抗雄激素治疗后的无转移生存:SPARTAN与ARAMIS研究的事后分析
本研究基于SPARTAN和ARAMIS两项3期临床试验的回顾性分析,按治疗期间血清睾酮维持水平(低于20 ng/dL与高于20 ng/dL)分组,采用逆概率治疗加权平衡基线特征,探讨睾酮水平与无转移生存(MFS)的关系。结果显示,在睾酮低于50 ng/dL的男性中,维持血清睾酮水平≥20 ng/dL与一线新型内分泌治疗nmCRPC患者较差的MFS无关,维持睾酮<20 ng/dL的预后价值有限,不提示需要进一步强化治疗。
要点
- 在SPARTAN和ARAMIS两项3期试验的事后分析中,血清睾酮水平与MFS在两项试验中均无统计学显著关联。
- 以低于20 ng/dL为参照,多变量Cox模型SPARTAN HR 0.68(95%CI 0.47-0.98;P<.05),ARAMIS HR 0.83(95%CI 0.57-1.20;P=.320)。
- 在睾酮<50 ng/dL的男性中,维持血清睾酮≥20 ng/dL与一线新型内分泌治疗nmCRPC较差的MFS无关。
核心结论
- 在所有睾酮<50 ng/dL的男性中,一线新型内分泌药物治疗nmCRPC时,维持血清睾酮水平≥20 ng/dL与较差的MFS无关。
- 维持睾酮水平<20 ng/dL在nmCRPC患者中的预后价值有限,不提示需要进一步强化治疗。
研究设计与样本
- 基于SPARTAN(NCT01946204)和ARAMIS(NCT02200614)两项3期临床试验的回顾性分析。
- 患者接受当前推荐的一线治疗方案(SPARTAN为雄激素剥夺治疗+阿帕他胺,ARAMIS为雄激素剥夺治疗+达罗他胺),按治疗期间血清睾酮维持水平分为低于20 ng/dL组和高于20 ng/dL组。
- 研究终点为无转移生存(MFS),采用逆概率治疗加权法平衡基线特征,并运用Kaplan-Meier分析、多变量Cox回归模型及将睾酮水平作为时依协变量的Cox模型进行分析。
主要发现
- 应用逆概率治疗加权后,低睾酮组与高睾酮组的基线特征平衡良好。
- Kaplan-Meier分析表明,两项试验中血清睾酮水平与MFS均无统计学显著关联。
- 以低于20 ng/dL为参照组,多变量Cox回归中SPARTAN的HR为0.68(95%CI 0.47-0.98;P<.05),ARAMIS的HR为0.83(95%CI 0.57-1.20;P=.320)。
- 时依Cox回归中SPARTAN的HR为0.84(95%CI 0.68-1.04;P=.110),ARAMIS的HR为1.21(95%CI 0.71-2.08;P=.480)。
- 将睾酮水平设为连续变量所得结果相似。
关键数值与推荐
- 欧洲泌尿外科学会指南和美国前列腺癌会议最新建议提出去势阈值为20 ng/dL。
- 当前美国国家综合癌症网络和AUA指南仍推荐去势标准为50 ng/dL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The European Association of Urology guidelines and the latest recommendations from the US Prostate Cancer Conference suggest a castration threshold of 20 ng/dL. However, the current National Comprehensive Cancer Network and AUA guidelines still recommend a castration standard of 50 ng/dL. It remains unknown whether there is a relationship between maintaining lower testosterone levels and the prognosis of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). MATERIALS AND METHODS: We conducted a retrospective analysis based on 2 phase 3 clinical trials (SPARTAN-NCT01946204, ARAMIS-NCT02200614). Patients receiving the currently recommended first-line treatment regimens (androgen deprivation therapy + apalutamide in SPARTAN and androgen deprivation therapy + darolutamide in ARAMIS) were classified into 2 groups according to their maintenance levels of serum testosterone during treatment: below 20 ng/dL and above 20 ng/dL. The study end point was metastasis-free survival (MFS). Inverse probability of treatment weighting method was used to balance patients' baseline characteristics. Kaplan-Meier analysis, multivariable Cox regression models, and Cox models that included testosterone levels as a time-dependent covariate were used to investigate the influence of maintenance levels of serum testosterone on MFS. RESULTS: Baseline characteristics were well balanced between the low testosterone group and the high testosterone group after applying inverse probability of treatment weighting weights. Kaplan-Meier analysis indicated that there was no statistically significant association between serum testosterone levels and MFS in either trial. In both multivariable Cox regression models and time-dependent Cox regression models, the relationship between serum testosterone levels and MFS did not show statistical significance either, using below 20 ng/dL as the reference group (multivariable Cox: SPARTAN HR, 0.68 [95% CI, 0.47-0.98; P < .05], ARAMIS HR, 0.83 [95% CI, 0.57-1.20; P = .320]; time-dependent Cox: SPARTAN HR, 0.84 [95% CI, 0.68-1.04; P = .110], ARAMIS HR, 1.21 [95% CI, 0.71-2.08; P = .480]). The results obtained by setting testosterone levels as a continuous variable were similar. CONCLUSIONS: Among all men with testosterone < 50 ng/dL, maintenance serum testosterone levels ≥ 20 ng/dL were not associated with poorer MFS in the first-line therapy of nmCRPC with novel hormonal agents. The prognostic value of maintaining testosterone levels < 20 ng/dL in patients with nmCRPC is limited, and further treatment intensification is not indicated. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01946204, NCT02200614.
引用
- Ni X, Sui J, Wang B, et al. Lower Testosterone Level and Metastases-Free Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With Novel Antiandrogens: A Post Hoc Analysis of SPARTAN and ARAMIS. J Urol. 2025. PMID: 40132221. doi:10.1097/JU.0000000000004545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。